MetaCap

Immuron (IMRN) vs Alaunos Therapeutics (TCRT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immuron is the larger company by market cap ($7.3 million vs $7.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMRN-17.45%TCRT+98.07%
+288%+125%-39%
Oct 7, 20261 yearNov 20, 2026
IMRN-16.69%TCRT+111.25%
+248%+106%-36%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMRN versus TCRT key metrics
MetricIMRNTCRT
Share price$0.8998$1.66
Market cap$7.26M$6.99M
1-day change+5.80%+3.75%
EPS (TTM)$-0.34$-1.76
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$5.00K
Revenue growth (YoY)—-50.00%
Net income (latest FY)—$-4.18M
Operating margin—-84500.00%
Net margin—-83520.00%
52-week high$1.99$4.50
52-week low$0.677$0.72
Distance from 52-week high-54.78%-63.11%
Analyst consensusnone—
Avg. price target upside+332.32%—
Average volume2.06M7.56M
Shares outstanding8.07M4.21M
Employees71
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Immuron

IMRN stock →

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Alaunos Therapeutics

TCRT stock →

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

IMRN vs TCRT FAQ

Which is bigger, Immuron or Alaunos Therapeutics?

Immuron (IMRN) is larger, with a market capitalization of $7.26M compared with $6.99M for Alaunos Therapeutics (TCRT).

Are Immuron and Alaunos Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons